Business

Researchers Examine Psilocybin Patent Claims

A patent granted to Compass Pathways is drawing attention to how pharmaceutical companies might end up owning forms of long-established psychedelic substances. Part 2 of a 3-part series.

Challenges to a Company’s Psilocybin Patent Highlight Contrasting Business Strategies for Developers of Psychedelic Therapies

Tactics used by Compass Pathways common to pharma companies pose ethical questions for the emerging psychedelics industry. Part one of a three-part series.